High-Dose Intravenous Vitamin C Combined with Chemotherapy:
An Early Clinical Study in Ovarian Cancer
One important direction in research on high-dose intravenous vitamin C (intravenous ascorbate) is to examine whether it can be used alongside standard chemotherapy while maintaining an acceptable safety profile and potentially reducing some chemotherapy-related adverse effects.
In ovarian cancer research, investigators conducted laboratory, animal, and human clinical studies. For patients, one of the most relevant components was a small randomised clinical trial evaluating the safety and early clinical findings of adding intravenous vitamin C to carboplatin and paclitaxel.
What Did the Study Do?
The study enrolled 27 patients with newly diagnosed stage III or stage IV ovarian cancer and randomly assigned them to standard chemotherapy alone or standard chemotherapy plus high-dose intravenous vitamin C.
27
Randomised Comparison of Standard Chemotherapy With or Without Intravenous Vitamin C
All patients received carboplatin plus paclitaxel as the main chemotherapy regimen.
One group additionally received high-dose intravenous vitamin C. The study focused primarily on safety, chemotherapy-related adverse effects, and exploratory signals involving disease progression and survival.
Twelve patients in the chemotherapy-only group were included in the main safety comparison.
12
Carboplatin + Paclitaxel
Thirteen patients received standard chemotherapy together with high-dose intravenous ascorbate.
13
Chemotherapy + High-Dose Intravenous Vitamin C
Did Severe Toxicity Increase After Intravenous Vitamin C Was Added?
One of the most notable findings from the human clinical component was that adding high-dose intravenous vitamin C did not show an increase in Grade 3 or Grade 4 severe toxicity.
No Increase
The Main Human Signal Was More About Safety and Tolerability
In this small randomised study, adding high-dose intravenous vitamin C to carboplatin and paclitaxel did not result in an apparent increase in Grade 3–4 treatment-related toxicity.
Neurological
Gastrointestinal
Dermatological
Other Lower-Grade Events
What Difference Was Observed in Time to Disease Progression?
The study also explored time to disease progression or recurrence and observed a numerical difference between the two groups. However, the difference did not reach statistical significance.
25.5
Months · IV Vitamin C + Chemotherapy
The reported time to disease progression or recurrence was approximately 25.5 months.
16.75
Months · Chemotherapy Alone
In the standard chemotherapy-only group, the reported time was approximately 16.75 months.
The 25.5 vs 16.75 Month Difference Was Not Statistically Significant
This numerical difference should therefore be viewed only as an early signal that may justify further investigation. The study was not large enough to demonstrate that high-dose intravenous vitamin C improves progression-free survival or overall survival.
How Should This Study Be Interpreted?
An important feature of this study is that it moved beyond examining intravenous vitamin C in isolation and began exploring its safety and tolerability when administered alongside standard chemotherapy.
Adding high-dose intravenous vitamin C did not show an apparent increase in Grade 3–4 toxicity.
No Clear Increase in Severe Toxicity
Selected Grade 1–2 chemotherapy-related adverse events were reported less often in the intravenous vitamin C group.
Some Mild-to-Moderate Adverse Effects Were Less Frequent
The sample was very small, and the difference in disease progression time did not reach statistical significance.
Clinical Efficacy Remains Unconfirmed
A More Appropriate Conclusion Is a Safety Signal with Fewer Selected Lower-Grade Adverse Events
In this small ovarian cancer study, high-dose intravenous vitamin C used with carboplatin and paclitaxel did not clearly increase severe toxicity and was associated with fewer selected mild-to-moderate chemotherapy-related adverse events. These findings are not sufficient to establish that high-dose vitamin C improves chemotherapy efficacy or prolongs survival.
Why Is This Study Worth Attention?
In addition to the human clinical component, the study included cell and animal experiments exploring how millimolar ascorbate might influence ovarian cancer cells and their sensitivity to chemotherapy.
01
Pro-Oxidant Activity
Under specific experimental conditions, millimolar ascorbate may exhibit pro-oxidant activity.
Hydrogen Peroxide Formation
Experimental work involved hydrogen peroxide formation and related oxidative stress mechanisms.
03
DNA Damage
Changes associated with DNA damage were also observed in the experimental models.
04
Altered Energy Metabolism
ATP depletion and changes in cellular metabolic pathways were also implicated in the experimental effects.
Cell and Animal Mechanisms Cannot Be Directly Equated with Human Clinical Outcomes
Laboratory and animal studies can help explain biological mechanisms and generate research hypotheses, but they cannot establish that patients in real-world clinical settings will experience the same tumour-control or survival outcomes.
How Does BMS Clinic View This Evidence?
This study suggests that the role of high-dose intravenous vitamin C in patients with cancer is better considered within a complete medical care plan rather than as a standalone intervention.
For patients receiving carboplatin, paclitaxel, or other cancer medicines, consideration of this type of medical support should include current disease status, existing medications, kidney function, G6PD status, and other individual risk factors.
BMS Clinic emphasises professional assessment based on current medical evidence and individual circumstances. Early findings involving fewer selected chemotherapy-related adverse events and numerical differences in disease progression still require confirmation in larger studies and should not be interpreted as established clinical efficacy.
This article is provided for medical education and literature reference only. It does not replace diagnosis, assessment, or personalized medical advice from a qualified healthcare professional.
This was a small, early-stage randomized clinical study primarily providing safety and preliminary clinical data. Although differences in some chemotherapy-related adverse effects and time to disease progression were observed, the findings are insufficient to establish that high-dose intravenous vitamin C improves chemotherapy efficacy, controls ovarian cancer, or prolongs survival.
Patients with cancer considering this or other supportive medical approaches should first undergo professional assessment based on their individual condition, current cancer care, and relevant risk factors.
Learn More About High-Dose Intravenous Vitamin C Used Alongside Chemotherapy
This early ovarian cancer study primarily provides safety and preliminary clinical data on high-dose intravenous vitamin C used alongside Carboplatin and Paclitaxel. Fewer mild-to-moderate chemotherapy-related adverse effects were observed in some areas, but the difference in time to disease progression was not statistically significant and should not be interpreted as proven treatment efficacy. Patients receiving chemotherapy should undergo professional assessment based on their current medications, disease status, kidney function, G6PD status and other individual risk factors before considering this type of medical support.
References
Ma Y, Chapman J, Levine M, Polireddy K, Drisko J, Chen Q. High-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014;6(222):222ra18.
National Cancer Institute. Intravenous Vitamin C (PDQ®) – Health Professional Version. Evidence review of intravenous vitamin C in cancer.